RESUMO
BACKGROUND: Androgenetic alopecia is a common condition of adult men. Finasteride, a type 2 5alpha-reductase inhibitor, decreases the formation of dihydrotestosterone from testosterone. OBJECTIVE: Two separate clinical studies were conducted to establish the optimal dose of finasteride in men with this condition. METHODS: Men from 18 to 36 years of age with moderate vertex male pattern hair loss received finasteride 5, 1, 0.2, or 0.01 mg/day or placebo based on random assignment. Efficacy was determined by scalp hair counts, patient self-assessment, investigator assessment, and assessment of clinical photographs. Safety was assessed by clinical and laboratory measurements and by analysis of adverse experiences. RESULTS: Efficacy was demonstrated for all end points for finasteride at doses of 0.2 mg/day or higher, with 1 and 5 mg demonstrating similar efficacy that was superior to lower doses. Efficacy of the 0.01 mg dose was similar to placebo. No significant safety issues were identified in the trials. CONCLUSION: Finasteride 1 mg/day is the optimal dose for the treatment of men with male pattern hair loss and was subsequently identified for further clinical development.
Assuntos
Inibidores de 5-alfa Redutase , Alopecia/tratamento farmacológico , Inibidores Enzimáticos/administração & dosagem , Finasterida/administração & dosagem , Adolescente , Adulto , Alopecia/sangue , Di-Hidrotestosterona/sangue , Método Duplo-Cego , Cabelo/efeitos dos fármacos , Cabelo/crescimento & desenvolvimento , Humanos , Masculino , Satisfação do PacienteRESUMO
BACKGROUND: Preclinical study and human patch tests indicate polyolprepolymer-2 may reduce cutaneous tretinoin-induced irritation. OBJECTIVE: This study compared the clinical efficacy and safety of a 0.025% tretinoin cream containing polyolprepolymer-2 and its vehicle to a commercially-available 0.025% tretinoin cream. METHODS: In this 12-week multicenter, double-blind, parallel group study in patients with mild to moderate acne, objective lesion counts and the investigators' global evaluations evaluated efficacy. Subjective evaluations of skin irritation were used to study safety. RESULTS: A total of 271 patients were enrolled. The active treatments demonstrated comparable efficacy that was statistically significantly greater than that of the vehicle. Safety evaluations of cutaneous and noncutaneous adverse events also indicated comparable results of the active treatments. CONCLUSION: The commercially-available 0.025% tretinoin cream and the 0.025% tretinoin cream containing polyolprepolymer-2 demonstrated comparable efficacy and safety.
Assuntos
Acne Vulgar/tratamento farmacológico , Ceratolíticos/administração & dosagem , Tretinoína/administração & dosagem , Administração Tópica , Adulto , Método Duplo-Cego , Feminino , Humanos , Ceratolíticos/efeitos adversos , Ceratolíticos/química , Masculino , Pomadas , Polipropilenos/administração & dosagem , Poliuretanos/administração & dosagem , Tretinoína/efeitos adversos , Tretinoína/químicaAssuntos
Calcitriol/análogos & derivados , Clobetasol/análogos & derivados , Fármacos Dermatológicos/uso terapêutico , Psoríase/tratamento farmacológico , Vasoconstritores/uso terapêutico , Administração Cutânea , Adulto , Calcitriol/administração & dosagem , Calcitriol/uso terapêutico , Clobetasol/administração & dosagem , Clobetasol/uso terapêutico , Fármacos Dermatológicos/administração & dosagem , Combinação de Medicamentos , Feminino , Humanos , Masculino , Pomadas , Indução de Remissão , Vasoconstritores/administração & dosagemRESUMO
BACKGROUND: The topical vitamin D analogue calcipotriene has been reported to be an effective treatment for patients with psoriasis. Comparative studies with topical steroids are informative in judging this new therapy. OBJECTIVE: The purpose of this study was to evaluate the efficacy and safety of calcipotriene ointment 0.005% versus fluocinonide ointment 0.05% in the treatment of plaque psoriasis. METHODS: This study was a randomized, double-blind, parallel-group, active-controlled trial in adults who had at least mild overall disease severity and plaque elevation of at least moderate severity. Treatments were applied twice daily for 6 weeks, and subjects were evaluated at weeks 0, 2, 4, and 6. Subjects were graded on a 9-point scale (0 to 8) for scaling, erythema, plaque elevation, and for overall disease severity. A physician's global assessment of improvement/worsening was performed at every visit. RESULTS: A total of 114 subjects were enrolled at six study sites. Ninety-nine subjects completed the trial. Mean scores for signs of scaling and plaque elevation in calcipotriene-treated subjects were significantly lower by week 2 than in the fluocinonide-treated subjects. These scores continued to be significantly lower than fluocinonide through week 6 (p < 0.05). Mean scores for erythema in calcipotriene-treated subjects were significantly lower than those in fluocinonide-treated subjects at weeks 4 and 6 (p < 0.05). Both the physician's global assessment and overall disease severity showed statistically significant treatment differences in favor of calcipotriene at week 4 (p < 0.05). This superior efficacy continued through week 6. Treatment-related adverse events were observed in 12 calcipotriene-treated subjects and 5 fluocinonide-treated subjects; all were considered minor. CONCLUSION: Calcipotriene was superior to fluocinonide in the treatment of plaque psoriasis.
Assuntos
Calcitriol/análogos & derivados , Fármacos Dermatológicos/uso terapêutico , Fluocinonida/uso terapêutico , Psoríase/tratamento farmacológico , Adulto , Idoso , Calcitriol/administração & dosagem , Calcitriol/efeitos adversos , Calcitriol/uso terapêutico , Fármacos Dermatológicos/administração & dosagem , Fármacos Dermatológicos/efeitos adversos , Método Duplo-Cego , Feminino , Fluocinonida/administração & dosagem , Fluocinonida/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Pomadas , Psoríase/patologia , Segurança , Fatores de TempoAssuntos
Fatores de Coagulação Sanguínea/metabolismo , Transtornos Plaquetários/sangue , Doenças de von Willebrand/sangue , Fator de von Willebrand/metabolismo , Adolescente , Adulto , Sítios de Ligação , Feminino , Humanos , Radioisótopos do Iodo , Masculino , Ristocetina/farmacologia , Síndrome , Fatores de TempoRESUMO
Eleven days after administration of multiple penicillin analogs, a 55-year-old female developed a Coombs-positive hemolytic anemia. The patient's erythrocytes were coated with IgG, complement components (C4/C3) and her serum contained elevated 125I-Clq binding activity (a measure of the presence of immune complexes). Her serum, in the presence of fresh complement and penicillin, induced complement sensitization of normal erythrocytes. Immune complex-mediated complement activation and the haptene type of erythrocyte sensitization accounted for accelerated red blood cell destruction in this patient.